GEHC – GE HealthCare Technologies Inc.

Comprehensive Monthly Stock Report: GE HealthCare Technologies Inc. (GEHC)

Publication Date: November 04, 2025

Company Overview

GE HealthCare Technologies Inc., headquartered in Chicago, Illinois, operates within the Health Information Services industry as part of the broader healthcare sector. The company specializes in the development, manufacture, and marketing of innovative products, services, and digital solutions designed for the diagnosis, treatment, and monitoring of patients. GE HealthCare’s business model is organized into four main segments:

1. Imaging: This division offers CT and MR imaging technologies.
2. Advanced Visualization Solutions (AVS): Focused on enhancing imaging clarity and diagnostic accuracy.
3. Patient Care Solutions (PCS): Supplies crucial patient monitoring devices.
4. Pharmaceutical Diagnostics (PDx): Provides diagnostic agents that are vital for various medical procedures.

With a strong presence not only in the United States and Canada, but also internationally, GE HealthCare Technologies aims to address the growing demand for health information solutions essential for improving patient care and operational efficiency within healthcare facilities. The company rebranded from GE Healthcare Holding LLC in December 2022, signifying a renewed focus on innovative healthcare solutions.

52-Week Price Performance Analysis

GE HealthCare Technologies Inc. (GEHC) has exhibited a predominantly bearish trend over the last year. The stock has fluctuated significantly, with a 52-week high of $94.80 and a 52-week low of $57.65, indicating a volatility range of approximately 38.80%. Currently priced at $74.44, the stock reflects a 15.38% decline from its high in March 2025.

Technical Insights

• Current Price: $74.44
• Fifty-Day Moving Average: $75.12 (indicating recent trading below this average)
• Resistance Level: $90 (previously faced rejection in March)
• Support Level: $70 (price consolidation period observed in May and June)

A green trend line on the stock’s chart suggests persistent selling pressure, as evidenced by lower highs and lower lows. The recent price movement shows a slight upward trend in October; however, GEHC remains entrenched below its moving average, reflecting ongoing bearish sentiment. Investors should closely monitor for any decisive breakouts above the moving average and trend line to signal a potential reversal in momentum.

Financial Performance and Metrics

Financial results for the third quarter of 2025 have displayed strong performance, with revenues reaching $5.14 billion, exceeding the analyst consensus estimate of $5.08 billion. This uptick was largely driven by strong demand for medical devices, particularly in the U.S. and EMEA regions. Key financial metrics include:

• Total Revenue: $20.25 billion (for the year)
• Adjusted Earnings Per Share (EPS): Projected range of $4.51 to $4.63, an increase from previous estimates.
• EBITDA: Approximately $3.63 billion, showcasing robust operational profitability.

The stock’s current price undervalues its potential, supported by a projected high target price of $108.00, a mean target of approximately $88.44, and a median price of $87.00. This represents an attractive investment opportunity for growth-oriented investors.

Recent News and Developments

Several impactful developments have emerged:

1. Third Quarter Results: Strong performance with revenues of $5.14 billion, prompting an upward revision of the 2025 adjusted profit forecast. However, it was noted that sales in China declined by 3% to $547 million, reflecting market challenges due to a government anti-corruption campaign and slowed stimulus measures.

2. Expansion of Monitoring Solutions: On October 22, 2025, GE HealthCare received the CE mark for its Carevance patient monitor, facilitating access to advanced patient monitoring solutions in Europe. This innovative platform will enhance perioperative hypotension management without requiring additional hardware or invasive procedures.

3. Analyst Upgrades and Endorsements: Positive analyst sentiment prevails, with Exane BNP Paribas reiterating an “Outperform” rating and a price target of $92. Stifel Nicolaus and Oppenheimer maintained their “Buy” ratings, with price targets of $90 and $89, respectively.

Market Sentiment and Analyst Recommendations

Overall market sentiment for GE HealthCare Technologies Inc. is cautiously optimistic, highlighted by:

• Average Recommendation: Buy (Mean recommendation score at 1.77)
• Analyst Consensus: Endorsements from 21 analysts suggesting confidence in the company’s future performance.
• Short Interest: Approximately 0.0229% of float shares are sold short, indicating a predominantly positive outlook among long-term investors.

Despite current challenges, such as declining sales in specific regions and the stock’s underperformance relative to its moving average, the prevailing analyst consensus supports investment due to the expected growth potential in the healthcare technology sector.

Conclusion

Investors considering GE HealthCare Technologies Inc. (GEHC) should weigh both the opportunities presented by its robust financial health and service innovations against the risks of market volatility and economic challenges. While the stock is currently priced at $74.44, the projected price targets suggest significant upside potential, positioning it as a strong investment candidate within the expanding healthcare technology sector.

As investors navigate the complexities of the stock market, GE HealthCare Technologies stands out as a compelling opportunity, promising innovative advancements necessary for modern medical care amidst a backdrop of increasing investor confidence.

Metric	Value
Market Cap	$33.9b
Total Debt	$10.7b
Total Cash	$4.0b
Shares Outstanding	455.5m
Float Shares	454.2m